#Dr.Anil-Angrish Archive

Editorial & Columns

Indian Pharmaceutical Industry in Consolidation Mode

November 27, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Indian Pharmaceutical Companies: Investment in R&D for “Jai Anusandhan”

September 25, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Forex Rate Risk: Measurement and Mitigation by Pharmaceutical Companies in India

September 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Skin in the Game: Decrease in Promoter Holding of Pharmaceutical Companies in India

September 4, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Different Routes and Same Destination: Indian Pharmaceutical & FMCG Companies in Wellness Segment

August 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Risk Management and Pharmaceutical Companies in India

August 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Voluntary Licensing in Pharmaceutical Industry: Impact on Market Access & Pricing

August 1, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Competitive Intelligence in Pharmaceutical Industry

July 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

India and Group of Seven (G7): Connected through Pharmaceuticals

June 21, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Accessibility and Affordability of Biologics in Low-Middle Income Countries

June 12, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

1
2

Contact Us